Research conducted with support of AI tools (Open Evidence & Claude)

Oral micronized progesterone (OMP) has become the default progestogen choice for many clinicians prescribing menopausal hormone therapy (MHT). The research supporting its superior safety profile over synthetic progestins is genuinely strong, but a question has been gaining traction in some clinical circles that deserves more exploration.

Dr. Felice Gersh has put some star power behind a small but growing concern that nightly OMP use, via its primary oral metabolite, allopregnanolone, may have some negative impacts in the brain. Her argument is not against progesterone itself. Her concern is specific to the oral route of administration of progesterone and what happens, particularly in the brain, when postmenopausal women take it every night for decades, which has not been studied (to cut to the chase). It is a question worth sitting with, even if the final answer isn't in yet.

This article reviews what the published evidence supports, where the uncertainty lies, how I understand Dr. Gersch’s point of view and where that comes from, and what protocol adjustments may be worth considering if this is a concern for you in your practice.

Our goal is never to suggest that providers practice outside of clinical guidelines, but to provide an informed view of what the evidence shows so you can make individualized decisions for your patients.

OMP Safety Profile

We have to begin this conversation by affirming that OMP has been shown to be a very safe option, and a safer option than synthetic progestins for MHT.

Breast Cancer Risk

The differentiation between micronized progesterone and synthetic progestins on breast cancer risk is one of the more consistent findings across the menopause literature. A systematic review and meta-analysis by Asi et al. (2016) pooled data from 86,881 postmenopausal women and found that progesterone was associated with a 33% lower breast cancer risk compared to synthetic progestins when combined with estrogen (RR 0.67; 95% CI 0.55–0.81).

You may recall that the Women's Health Initiative (WHI) identified a slight increased risk of breast cancer in women on combined MHT, but those women were on medroxyprogesterone acetate (a synthetic progestin), were well past the optimal timing window for hormone initiation, and were older than the typical patient we are treating today. That context matters.

A separate systematic review concluded that estrogens combined with OMP do not increase breast cancer risk for up to five years of use. Beyond five years, data remain limited — a gap the International Menopause Society has acknowledged directly. The ongoing Swedish PROBES trial, a double-blind RCT comparing OMP to norethisterone acetate using mammographic density as the primary endpoint, should help fill that gap.

Cardiovascular and VTE Risk

A 2022 systematic review found that primary and recurrent VTE risk was not elevated by combining estrogens with micronized progesterone. This stands in contrast to certain synthetic progestogen classes, including norpregnane derivatives such as nomegestrol, which are more commonly used in Europe, as well as MPA, which carries its own VTE risk according to the WHI data.  Not all synthetic progestins carry equivalent risk, but OMP appears favorable across the board. Placebo-controlled RCTs assessing VTE as an adverse event showed no significant intergroup differences. Real-world US claims data from 2019 to 2021 added more specificity: women on oral estradiol/micronized progesterone had a 30% lower VTE risk than women on CEE/MPA (IRR 0.70; 95% CI 0.53–0.92).

On metabolic parameters, a clinical trial of 86 early postmenopausal women found that cyclic micronized progesterone did not negatively affect blood pressure, glucose, insulin, HDL, triglycerides, or hsCRP compared to estrogen alone.

Endometrial Protection

A systematic review of 40 studies by Stute et al. (2016) confirmed that OMP provides adequate endometrial protection when used sequentially at 200 mg/day for 12 to 14 days per month for up to five years. The British Menopause Society supports this dosing in sequential regimens, and notes that higher doses may be warranted in continuous combined regimens. Both the North American Menopause Society (NAMS) and the International Menopause Society (IMS) recognize OMP as a first-line option for endometrial protection in women on systemic estrogen, citing its favorable safety and tolerability profile over synthetic alternatives.

It is worth noting that some data suggest OMP's endometrial protection may be less robust than synthetic progestins at equivalent doses, particularly for longer-term use. This is a real tradeoff that belongs in the clinical conversation, not a reason to avoid OMP, but something to factor into monitoring decisions.

Sleep and Cognitive Effects

Because oral progesterone undergoes first-pass hepatic metabolism, it generates neurosteroid metabolites, most notably allopregnanolone, that act on GABA-A receptors. In the short term, this is clinically useful. A Phase III RCT by Prior et al. (2023) randomized 189 perimenopausal women to 300 mg OMP at bedtime versus placebo and found significant improvements in perceived sleep quality (P=0.005) and perimenopause-related life interference (P=0.017), with no serious adverse events.

The KEEPS Continuation Study, published in PLOS Medicine in 2024, re-evaluated women from the original KEEPS trial approximately a decade after they completed four years of hormone therapy. The OMP protocol used in KEEPS was cyclic, 200 mg for 12 days per month, and the study found no cognitive harm associated with this regimen. In the transdermal estradiol arm specifically, there was evidence of better prefrontal cortex volume preservation compared to placebo, suggesting long-term structural brain benefit when hormone therapy is initiated early. That cyclic protocol detail matters, and we will come back to it.

The Allopregnanolone Question

Dr. Gersh's concern centers on what happens when oral progesterone is metabolized in the liver at the doses used nightly in clinical practice. Even at 100 mg, the lower end of the typical dosing range, oral progesterone generates allopregnanolone levels that exceed the peak of the natural luteal phase by approximately 2.5-fold. In a postmenopausal woman who has essentially no endogenous progesterone, that is a substantial neurosteroid exposure, repeated every night.

The physiologic data make this more notable, not less. Research measuring serum allopregnanolone across the menstrual cycle found that while both allopregnanolone and progesterone rise from the follicular to luteal phase, the allopregnanolone-to-progesterone ratio actually decreases 8-fold in the mid-luteal phase. The body actively limits this conversion as progesterone rises. Oral dosing bypasses that regulatory mechanism entirely.

The GABA-A Parallel

Allopregnanolone is a positive allosteric modulator of GABA-A receptors, which puts it in the same mechanistic class as benzodiazepines, though it binds at a distinct site. Dr. Gersh draws an analogy that is worth considering: we have decades of data showing chronic benzodiazepine use produces tolerance, receptor downregulation, and long-term cognitive impairment. She asks whether nightly supraphysiologic allopregnanolone exposure might carry similar risks over time.

That risk has been called out by the FDA about a pharmaceutical-grade analog of allopregnanolone, Brexanolone (Zulresso), which is approved for postpartum depression. Brexanolone is a DEA Schedule IV controlled substance, the same schedule as benzodiazepines, specifically because the DEA determined its pharmacological mechanism and abuse potential are similar to Schedule IV sedative-hypnotics such as diazepam and midazolam.

What the Basic Science Shows

The published basic science supports the biological plausibility of Dr. Gersh's concern. A 2011 paper in the British Journal of Pharmacology (Turkmen et al.) found that chronic allopregnanolone treatment results in reduced GABA-A receptor responses in isolated cortical neurons, consistent with the tolerance pattern seen with benzodiazepines. During pregnancy, when allopregnanolone is naturally elevated, GABA-A receptor subunit composition changes in parallel, and the marked sedation of early pregnancy fades as levels continue to rise, suggesting the brain is actively adapting to the exposure.

A review in Frontiers in Endocrinology noted that chronically high GABA-steroid exposure has been associated with irreversible cognitive damage in preclinical models. In rodent spatial memory tasks, overactivation of GABA-A receptors by allopregnanolone impaired learning and memory. A human study by Kask et al. (2008) administered IV allopregnanolone to healthy women and found measurable episodic memory impairment, though with significant individual variability.

Perhaps the most striking finding comes from transgenic Alzheimer's disease animal models: continuous allopregnanolone exposure at physiological levels impaired cognition and increased degenerative pathology, while intermittent injections had the opposite effect, enhancing cognition. The pattern of exposure appears to matter as much as the dose. One has to wonder how the results of this study would look if exposure levels were 2-3 times higher than physiological levels.

The Honest Scope of the Evidence

Dr. Gersh is explicit that the dementia concern is derived from animal studies, not long-term human RCT data. No adequately powered human trial has examined nightly OMP specifically through a neurocognitive safety lens over a decade or more. The absence of that data is not evidence of harm. It is also not evidence of safety.  It is a research gap.

The KEEPS Continuation data is reassuring, but carries an important caveat: KEEPS used 200 mg OMP for only 12 days per month. The cumulative allopregnanolone exposure in that model is substantially lower than what a woman taking 100 or 200 mg every night would accumulate. Those are meaningfully different pharmacological exposures, and we should not conflate them.  Keep this in mind, as a cyclic progesterone regimen like the one used in the KEEPS trial is a suitable approach for MHT which may be a better option if cognitive health is a concern.

Cyclic OMP as a Protocol Consideration

If the concern with continuous nightly OMP centers on chronic supraphysiologic allopregnanolone exposure, then cyclic protocols represent a straightforward way to reduce that exposure while maintaining endometrial protection and the known safety advantages over synthetic progestins, and staying well within standard practice guidelines.

The KEEPS data make the strongest case here. Sequential OMP at 200 mg for 12 days per month was not associated with cognitive harm at long-term follow-up, and the women on transdermal estradiol in that trial had better structural brain outcomes than those on placebo. Cyclic protocols also inherently build in periods of GABA-A receptor recovery, which the basic science suggests may be relevant.

Stute et al.'s systematic review confirmed that sequential OMP at 200 mg for 12 to 14 days per month provides adequate endometrial protection for up to five years. This is guideline-supported dosing, not an off-label workaround. For patients with cognitive concerns, a family history of dementia, or who are anticipated to be on therapy for extended periods, it is a protocol worth defaulting to.

Vaginal Progesterone: A Real Option, but with Real Limits

Vaginal progesterone is frequently proposed as the solution to the allopregnanolone problem. The logic is straightforward: bypassing first-pass hepatic metabolism means lower systemic and CNS allopregnanolone exposure, while the uterine first-pass effect allows progesterone to reach the endometrium efficiently at relatively low serum concentrations.

For patients who cannot tolerate OMP due to side effects like sedation or dizziness, vaginal progesterone is a clinically reasonable option. But practitioners need to go in with clear eyes about what the endometrial protection data actually looks like for this route in the context of MHT.

A 2025 editorial in Gynecological Endocrinology put it directly: vaginal micronized progesterone continues to raise concerns regarding the adequacy of endometrial protection. A systematic review of progestogens for endometrial protection in MHT found that vaginal progesterone at 45 mg/day for 10 days per month, which was the ELITE study’s protocol, was the only vaginal regimen with RCT-level endometrial protection evidence. Most other vaginal progesterone use in MHT remains off-label in the majority of countries, without the same evidence base that exists for oral dosing.

The IMS 2024 white paper acknowledged that vaginal administration may be better tolerated in progestogen-sensitive patients but was clear that regular monitoring with ultrasonography and/or endometrial biopsy is critical when using suboptimal or off-label doses. One observational study found no cases of endometrial hyperplasia or cancer in women using transdermal estradiol with vaginal micronized progesterone. This is a reassuring signal, but not a substitute for RCT data.

Vaginal progesterone is a legitimate clinical tool. Until larger trials affirm its safety, it should be used with the understanding that endometrial surveillance needs to be more active than it would be with standard oral dosing protocols.  

Where This Leaves Clinical Practice

The established evidence base for OMP is real and clinically meaningful. Its safety advantages over synthetic progestins, particularly around breast cancer risk and VTE, are not in dispute.

What this conversation raises is a more specific question: whether continuous nightly oral dosing, with its repeated supraphysiologic allopregnanolone peaks, represents the optimal long-term protocol from a neurocognitive standpoint. That question has not been answered by the existing human data, because the studies that would answer it have not been done.

For most women in early menopause, OMP remains a well-supported choice. There are good reasons to prefer cyclic over continuous protocols where endometrial protection can be reliably achieved, particularly for patients on therapy for five or more years or those with cognitive concerns. For patients who cannot tolerate oral progesterone, vaginal delivery is a reasonable alternative with the caveat that endometrial monitoring needs to be closer.

This is a field that continues to evolve, and asking better questions is how it gets there. Dr. Gersh is asking one worth taking seriously.

References

1. Asi N, Mohammed K, Haydour Q, et al. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Syst Rev. 2016;5(1):121. doi:10.1186/s13643-016-0294-5

2. Stute P, Neulen J, Wildt L. The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric. 2018;21(2):111-122. doi:10.1080/13697137.2017.1421925

3. Henriksson P, et al. The impact of micronized progesterone on cardiovascular events: a systematic review. Climacteric. 2022. PMID:35112635

4. Panay N, et al. Oral estradiol/micronized progesterone may be associated with lower risk of VTE compared with CEE/MPA. Maturitas. 2023. doi:10.1016/j.maturitas.2023.03.006

5. Stute P, et al. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric. 2016;19(4):316-328. doi:10.1080/13697137.2016.1187123

6. Prior JC, et al. Oral micronized progesterone for perimenopausal night sweats and hot flushes: a Phase III RCT. Sci Rep. 2023. doi:10.1038/s41598-023-35826-w

7. Memi E, Pavli P, Papagianni M, Vrachnis N, Mastorakos G. Diagnostic and therapeutic use of oral micronized progesterone in endocrinology. Rev Endocr Metab Disord. 2024;25(4):751-772. doi:10.1007/s11154-024-09882-0

8. Gleason CE, et al. Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study. PLOS Med. 2024. doi:10.1371/journal.pmed.1004435

9. Turkmen S, et al. Tolerance to allopregnanolone with focus on the GABA-A receptor. Br J Pharmacol. 2011;162(2):311-327. PMC3031054

10. Backstrom T, et al. Neurosteroids and GABA-A receptor function. Front Endocrinol. 2011;2:44. PMC3356040

11. Kask K, et al. Allopregnanolone impairs episodic memory in healthy women. Psychopharmacology. 2008;199(3):161-168. doi:10.1007/s00213-008-1150-7

12. Kimball A, et al. The allopregnanolone to progesterone ratio across the menstrual cycle and in menopause. Psychoneuroendocrinology. 2020. doi:10.1016/j.psyneuen.2019.104479

13. Gersh F. (Podcast, 2025). Connection of Progesterone, Estrogen, and Hashimoto's (Part 2). Inna Topiler Health podcast.

14. Gersh F. (Podcast, 2025). Is Estrogen Replacement Safe? Dr. Brighten podcast.

15. Casanova G, Spritzer PM. Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors. Lipids Health Dis. 2012. PMC3508911

16. British Menopause Society. Tool for Clinicians: Progestogens and endometrial protection. 2026.

17. Lindberg J, et al. PROBES trial: breast and endometrial safety of micronised progesterone versus norethisterone acetate. BMJ Open. 2024. PMC11499784

18. International Menopause Society. Menopause and MHT in 2024: key controversies — IMS White Paper. Climacteric. 2024. doi:10.1080/13697137.2024.2394950

19. Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use. Adv Pharmacol Pharm Sci. 2012. doi:10.1155/2012/416864

20. Xie YX, et al. Oral versus vaginal micronized progesterone in menopausal hormone therapy. Gynecol Endocrinol. 2025;41(1). doi:10.1080/09513590.2025.2592400